Indalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965

Key milestone reached in adaptive Phase 1/1b clinical trial that began in April 2019 Cambridge, MA, October 21, 2019 – Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH), today announced that the first IPF patient has been […]

CoapTech LLC Awarded $1.2M Grant from National Institutes of Health to Support Clinical Evaluation and Training for Novel PUMA-G Device

BALTIMORE, Md., Oct. 21, 2019 (GLOBE NEWSWIRE) — CoapTech LLC announced today that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) within the National Institutes of Health (NIH) awarded the company a two-year, $1.2M R44 Small Business Innovation Research (SBIR) Phase II grant on August 29, 2019. This builds on a $225,000 Phase […]

Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines

CAMBRIDGE, Mass., and GAITHERSBURG, Md., – October 7, 2019:– Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agreement. Editas Medicine will use MaxCyte’s Flow Electroporation® technology and ExPERT™ instruments for the advancement of engineered cell […]

KaloCyte Relocates to Downtown Baltimore as Co-Founders Join University of Maryland Faculty

Biotechnology Company Is Developing Synthetic Blood Product for Use in Trauma Settings BALTIMORE, Sept. 23, 2019 /PRNewswire/ — KaloCyte, a preclinical-stage healthcare biotechnology company developing a synthetic, bio-inspired red blood cell substitute for use in settings when stored red blood cells are not available, has joined Baltimore’s growing biotech community as a University of Maryland […]

Facility Logix Highlights Firm’s Significant Growth as It Celebrates 15th Anniversary

National Biotech Facility Consulting Firm Continues to Gain Traction in Milestone Year on Heels of Recent Project Completion for United Therapeutics and Academic Medical Center in the Southeast Burtonsville, MD – September 19, 2019 – Facility Logix, a life sciences consulting firm providing best-in-class customized facility solutions and novel approaches to facility design, real estate construction and project […]

BioBuzz: MaxCyte CEO and Co-Founder Doug Doerfler Among the Featured Serial Entrepreneurs of the Biohealth Capital Region

Serial Entrepreneurs of the Biohealth Capital Region A strong group of entrepreneurs ready and willing to innovate, fund and lead new bioscience companies is essential to the creation and sustainability of top-tier biohealth clusters. It is often referenced that the BioHealth Capital Region (BHCR) lacks a deep enough pool of qualified executive talent that is […]

BioBuzz: GlycoMimetics CEO Rachel King Among Female Execs Setting Standard of Excellence in Biohealth Capital Region

Liftstream, a U.K.-based executive recruiting firm, released an oft referenced report called “A Public Reality for Women in Biotech Boardrooms” in 2016. Lifstream’s research found that only 7 to 9 percent of biotech CEOs were women, less than 11 percent of board seats were held by females and 98 percent of board chair positions were held by […]

BBJ: Md. Tech Council CEO wants state biotech industry to aim higher than “top 3”

“Why would you shoot for No. 3?” Maryland Tech Council CEO Marty Rosendale wants to unite companies and legislators around making Maryland into the No. 1 destination for biotech firms in the U.S. Click here to read more via the Baltimore Business Journal (Subscription Required)

3-V Biosciences Changes Name to Sagimet Biosciences and Closes $25 Million Financing

Name connotes expertise in fatty acid metabolism and therapeutic focus targeting dysfunctional metabolic pathways SAN MATEO, Calif., Aug. 5, 2019 /PRNewswire/ — 3-V Biosciences, a clinical-stage biotechnology company, announced today that it has changed its name to Sagimet Biosciences and closed a second tranche of its Series E financing, which now totals $25 million. Sagimet’s lead product candidate, the […]

MaxCyte Founder, President and CEO Doug Doerfler joins Rich Bendis on BioTalk

MaxCyte Founder, President and CEO Doug Doerfler joins BioTalk to discuss his history and the growth of the company. He also shares advice for entrepreneurs Mr. Doerfler has more than 35 years of experience in the discovery, development, commercialization and international financing of biotechnology products and companies. He was a founder of MaxCyte in July […]

PressComm

News